This is an old revision of the document!
Summary of research on aging and OlmesartanMedication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. Also known by the trade name Benicar. taken from article Science behind olmesartan
benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. 1)
In conclusion, there is no robust signal for harm with olmesartan use. 2)
include the ability to:
to block various bad effects of Angiotensin II, including heart failure. In this regard, olmesartan has been shown to:
In August 2002, Trevor Marshall and Frances Marshall published a NetPrint about valsartan (Diovan), in which they reported that the once daily dosing of the ARBA drug which is an angiotensin receptor blocker. One of the ARBs is olmesartan (Benicar). Not all ARBs activate the Vitamin D Receptor. caused psychedelic dreams and psychotic events in two sarcoidosis patients. On the theory that these symptoms were caused by changes in plasma concentration, the frequency of the dosing of ARB was increased, which ended up reducing symptoms of disease including psychedelic dreams. This early insight into ARBs anti-inflammatory effects led Marshall to conclude that for an ARB to provide symptomatic relief, it was necessary to use more frequent dosing than typical. Professor Marshall would later go on to recommend frequent dosing of another ARB, olmesartan.
In rats, Olmesartan at 6 mg/kg optimally reduced the inflammatory process and bone loss24). That would be 9-10 tablets of Olmetec daily for a 64 Kg human
that olmesartan and other ARBs possess various ways of protecting the kidneys from the effects of inflammation and cytokineAny of various protein molecules secreted by cells of the immune system that serve to regulate the immune system. damage:
Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint 43)